[Anti-TNF-alpha therapy for heart failure: etanercept, infliximab].
Matsumori
Akira
A
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D000068800:Etanercept; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use*; D000069285:Infliximab; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000502:physiology; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology*
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D016328:NF-kappa B; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept